ARTICLE | Company News
Alpharma, Durect deal
September 29, 2008 7:00 AM UTC
Durect granted Alpharma exclusive, worldwide rights to develop and commercialize Eladur bupivacaine transdermal patch to treat multiple indications. The patch has completed a Phase IIa trial to treat...